CN113456663B - Nanometer medicine generating device and application - Google Patents
Nanometer medicine generating device and application Download PDFInfo
- Publication number
- CN113456663B CN113456663B CN202110678804.7A CN202110678804A CN113456663B CN 113456663 B CN113456663 B CN 113456663B CN 202110678804 A CN202110678804 A CN 202110678804A CN 113456663 B CN113456663 B CN 113456663B
- Authority
- CN
- China
- Prior art keywords
- nano
- electrode
- generating device
- working medium
- power supply
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 100
- 239000013543 active substance Substances 0.000 claims abstract description 68
- 239000002245 particle Substances 0.000 claims abstract description 32
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000001301 oxygen Substances 0.000 claims abstract description 25
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 25
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000011882 ultra-fine particle Substances 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 20
- 230000008569 process Effects 0.000 claims abstract description 18
- 230000005684 electric field Effects 0.000 claims abstract description 17
- 238000001179 sorption measurement Methods 0.000 claims abstract description 15
- 230000009471 action Effects 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims description 63
- 150000003254 radicals Chemical class 0.000 claims description 42
- 230000000903 blocking effect Effects 0.000 claims description 23
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000006227 byproduct Substances 0.000 claims description 4
- 230000005611 electricity Effects 0.000 claims description 4
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 claims description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 3
- 239000000920 calcium hydroxide Substances 0.000 claims description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 230000003779 hair growth Effects 0.000 abstract description 8
- 230000003712 anti-aging effect Effects 0.000 abstract description 6
- 208000023504 respiratory system disease Diseases 0.000 abstract description 5
- 208000017520 skin disease Diseases 0.000 abstract description 5
- 206010072170 Skin wound Diseases 0.000 abstract description 3
- 230000006806 disease prevention Effects 0.000 abstract description 3
- 230000003796 beauty Effects 0.000 abstract description 2
- 230000003658 preventing hair loss Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 17
- 210000004881 tumor cell Anatomy 0.000 description 14
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000007943 implant Substances 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 239000013589 supplement Substances 0.000 description 10
- 210000002752 melanocyte Anatomy 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 239000004408 titanium dioxide Substances 0.000 description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 229960003160 hyaluronic acid Drugs 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229920001652 poly(etherketoneketone) Polymers 0.000 description 5
- 238000004381 surface treatment Methods 0.000 description 5
- 230000000287 tissue oxygenation Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010012434 Dermatitis allergic Diseases 0.000 description 4
- 239000011149 active material Substances 0.000 description 4
- 239000003570 air Substances 0.000 description 4
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 4
- 229960004039 finasteride Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000003467 diminishing effect Effects 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000037449 immunogenic cell death Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 238000006213 oxygenation reaction Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 238000006277 sulfonation reaction Methods 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 2
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000004195 gingiva Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical group [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000011506 response to oxidative stress Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000003803 hair density Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- -1 hydroxyl radicals Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical class [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000007076 release of cytoplasmic sequestered NF-kappaB Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05H—PLASMA TECHNIQUE; PRODUCTION OF ACCELERATED ELECTRICALLY-CHARGED PARTICLES OR OF NEUTRONS; PRODUCTION OR ACCELERATION OF NEUTRAL MOLECULAR OR ATOMIC BEAMS
- H05H1/00—Generating plasma; Handling plasma
- H05H1/24—Generating plasma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Plasma & Fusion (AREA)
- Biochemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a nano medicine generating device and application thereof. The high-voltage power supply system can be a high-voltage power supply or a transformer for providing a high-voltage electric field; the electrodes are respectively and electrically connected with two sides of the output end of the high-voltage power supply system and used for loading a high-voltage electric field. The working medium is subjected to electron avalanche process discharge under the action of a high-voltage electric field, so that at least one nano active substance of ultrafine particles, nitrogen-containing free radicals and oxygen-containing free radicals with the particle size of 0-1000 nanometers is obtained in a large area. The device is also provided with an adsorption layer or a filter layer to improve the purity of the nano medicine, intelligently adjust the components and the concentration of the nano active substance according to different purposes, and can be used for medical instruments such as skin diseases and wound care, beauty treatment and anti-aging, hair loss prevention, hair growth, oral care, respiratory disease prevention and treatment and the like.
Description
Technical Field
The invention relates to the field of medical equipment and health care management, in particular to a nano medicine generating device and application thereof.
Background
The traditional medicine administration mode generally adopts intravenous injection or oral administration. However, the traditional medicine treatment is expensive, the medicine utilization rate is low, the treatment effect is extremely limited, and the systemic side effect is large.
Due to its high activity, high permeability and low side effects, nano-drugs are becoming a new administration mode or drug carrier and are becoming a hot spot in current medical research.
In view of the above, the present invention provides a nano-drug generating device and application thereof.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides a nano medicine generating device and application.
In order to solve the technical problems, the following technical scheme is adopted:
the utility model provides a nano-drug generating device, includes high voltage power supply system and electrode pair, electrode pair includes electrode I and electrode II, one side electricity of high voltage power supply system's output is connected electrode I's tip, the opposite side electricity of high voltage power supply system's output is connected electrode II's tip, its characterized in that: the electrode I and the electrode II are oppositely arranged and are not contacted with each other;
the electrode I and the electrode II are used for loading a high-voltage electric field under the action of a high-voltage power supply system;
the nano medicine generating device also at least comprises a working medium, wherein the working medium is subjected to electron avalanche process discharge under the action of a high-voltage electric field between the electrode I and the electrode II, so that at least one nano active substance of ultrafine particles, nitrogen-containing free radicals and oxygen-containing free radicals with the particle size of 0-1000 nanometers is obtained.
Further, the nano-drug generating device further comprises a blocking medium, wherein the blocking medium is a medium with high dielectric constant, and the blocking medium is arranged between the electrode pairs to prevent the electrode pairs from discharging outside the working medium area, stabilize the high-voltage electric field and generate uniform ionization.
Further, the nano-drug generating device further comprises an adsorption layer, wherein the adsorption layer is arranged at the downstream of the electrode pair and is used for adsorbing byproducts in nano-active substances.
Further, the adsorption layer comprises at least one of calcium hydroxide, potassium hydroxide and sodium hydroxide for adsorbing nitrogen dioxide and ozone.
Further, the nano medicine generating device further comprises a filter layer, wherein the filter layer is arranged at the downstream of the electrode pair and is used for filtering out particles emitted by the electrode pair, particles with the particle size of more than 10 microns or other impurities entering from the outside.
Further, the filter layer is disposed at least one of upstream and downstream of the adsorbent layer.
Further, the nano-drug generating device also includes a supply member for providing a working medium and powering the flow of the working medium to cool the nano-drug generating device, maintaining an acceptably low temperature level.
Further, the supply member is also provided with a component concentration or flow sensor to maintain the proper composition and dosage of the working medium.
Further, the nano medicine generating device also comprises an intelligent sensor, wherein the intelligent sensor is used for detecting the concentration of at least one nano active substance of ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals and oxygen-containing free radicals, and intelligently adjusting the working parameters of the high-voltage power supply system, and the components and the dosage of the working medium.
Further, the nano active substance is low-temperature plasma with electron density of 10 7 -10 23 /cm 3 。
Further, the working medium is one or more of hyaluronic acid, collagen, water vapor, hydrogen, methane, oxygen, nitrogen, carbon dioxide, air, rare gas, essential oil, physiological saline or medicines.
Further, the electrode pairs are electrically connected by a partially ionized working medium or a broken down blocking medium during electron avalanche.
Further, the high-voltage power supply system is a high-voltage power supply or a transformer, and the output high voltage of the high-voltage power supply system is direct-current high voltage or alternating-current high voltage.
Further, the output high voltage of the high-voltage power supply system is a pulse high voltage.
According to another technical scheme, the application of the nano-drug generating device for relieving skin diseases is characterized in that the nano-drug generating device is used for providing a working medium to undergo electron avalanche process discharge to generate at least one nano-active substance containing ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals and oxygen-containing free radicals, wherein the nano-active substance or the nano-drug taking the nano-active substance as a carrier acts on skin, so that the oxygenation effect and the hemoglobin index of the skin are increased, the activation of mast cells and eosinophils is inhibited, the expression and the production of IL-6 and TNF-alpha are inhibited, the activation of NF- κB is inhibited, and allergic dermatitis is improved.
According to another technical scheme, the nano medicine generating device is used for generating nano active substances for oral care, the nano medicine generating device is used for providing a working medium to undergo electron avalanche process discharge to generate at least one nano active substance containing ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals and oxygen-containing free radicals, the nano active substances or nano medicines taking the nano active substances as carriers act on gingiva, periodontal or implant bodies, the hydrophilicity of the surfaces of the nano active substances is improved, bacteria inhibition and inflammation diminishing are achieved, periodontitis is relieved, growth of osteoblasts or tissue cells is promoted, wound healing is improved, and success rate of the implant bodies is improved.
According to another technical scheme, the application of the nano-drug generating device for relieving respiratory diseases comprises the steps that the nano-drug generating device is used for providing a working medium to undergo electron avalanche process discharge to generate at least one nano-active substance containing ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals and oxygen-containing free radicals, wherein the nano-active substance or nano-drug taking the nano-active substance as a carrier acts on respiratory tract, so that tissue oxygenation is improved, vasodilation is promoted, the level of inflammatory medium is improved, and regeneration of damaged tissue cells is promoted.
According to another technical scheme, the application of the nano-drug generating device for inhibiting tumor cells is that the nano-drug generating device is used for providing a working medium to be subjected to electron avalanche process discharge to generate at least one nano-active substance containing ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals and oxygen-containing free radicals, wherein the nano-active substance or nano-drug taking the nano-active substance as a carrier acts on tumor cells to activate macrophages, T cells or NK cells to induce immunogenic cell death of the tumor cells, and the system triggers specific and protective immune response, polarizes cell membranes, causes oxidative stress reaction and induces iron death of the tumor cells.
According to another technical scheme, the nano-active substance is generated by the nano-drug generating device and used for whitening and resisting aging, the nano-drug generating device is used for providing a working medium to undergo electron avalanche process discharge to generate at least one nano-active substance containing ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals and oxygen-containing free radicals, the nano-active substance or nano-drug taking the nano-active substance as a carrier acts on skin, so that oxygenation and tissue perfusion of the skin are improved, surface photoaged epidermal cells are removed, growth of collagen of the skin below is promoted, vascular endothelial growth factors are activated, and expression and tissue regeneration of anti-aging genes are promoted.
According to another technical scheme, the nano-drug generating device is used for generating nano-active substances for hair growth, the nano-drug generating device is used for providing a working medium to undergo electron avalanche process discharge to generate at least one nano-active substance containing ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals and oxygen-containing free radicals, the nano-active substances or nano-drugs taking the nano-active substances as carriers are used for scalp, the production of adenosine triphosphate is promoted, the DNA transcription factor of NF-kappa B, HIF-1 is activated, cell proliferation is promoted, the levels of cytokines, growth factors and inflammatory mediators are improved, tissue oxygenation is improved, and hair growth is promoted.
Due to the adoption of the technical scheme, the method has the following beneficial effects:
the invention relates to a nano medicine generating device and application, wherein a working medium is subjected to electron avalanche process discharge under the action of a high-voltage electric field between electrode pairs to obtain at least one nano active substance of ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals and oxygen-containing free radicals, an adsorption layer or a filter layer is further arranged to improve the purity of nano medicine, and the components and the concentration of the nano active substance are intelligently regulated according to different applications, so that the nano medicine generating device can be used for medical instruments such as skin diseases and wound nursing, beautifying and anti-aging, alopecia prevention, hair growth, oral care, respiratory disease prevention and treatment and the like.
The nano-drug generating device is also provided with a blocking medium, preferably a high dielectric constant medium, placed between the electrode pairs to stabilize the high voltage electric field and produce uniform ionization.
The nano medicine generating device is also provided with an adsorption layer or a filter layer for improving the purity of the nano medicine.
The nano-drug generating device is also provided with a supply component for providing a working medium and powering the flow of the working medium to cool the nano-drug generating device and maintain an acceptably low temperature level.
The supply member is also provided with a component concentration or flow sensor to maintain the proper composition and dosage of the working medium.
The nano medicine generating device also comprises an intelligent sensor, wherein the intelligent sensor is used for detecting the concentration of at least one nano active substance of ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals and oxygen-containing free radicals, and intelligently adjusting the working parameters of the transformer, the components and the dosage of the working medium, so that the components and the concentration of the nano active substances are adjusted, and different purposes and requirements are met.
The nanometer active substance is low-temperature plasma with electron density of 10 7 -10 23 /cm 3 。
The output high voltage of the high-voltage power supply system is preferably pulse high voltage, so that the working temperature is reduced and the biocompatibility is improved while the nano-medicine is efficiently manufactured. In addition, the nano medicine generating device can continuously work for a long time, is stable in work, safe and effective, high in purity and small in size, and can be applied to various medical instruments and health care.
Drawings
The invention is further described below with reference to the accompanying drawings:
fig. 1 is a schematic structural view of a nano-drug generating device according to a first embodiment of the present invention;
fig. 2 is a schematic structural diagram of a nano-drug generating device according to a second embodiment of the present invention;
FIG. 3 is a graph showing the concentration of ultrafine particles having a partial particle diameter (11.5-64.9 nm) generated by a nano-drug generating device according to the present invention;
FIG. 4 is a graph of the spectrum of hydroxyl radicals (ESR tester) generated by the nano-drug generating device according to the present invention;
FIG. 5 is a graph of NO concentration produced by a nano-drug generating device according to the present invention;
FIG. 6-1 is a stratum corneum view of M2 type macrophages prior to treatment;
FIG. 6-2 is a stratum corneum view of M2 type macrophages after treatment;
FIG. 6-3 is a glandular view of M2-type macrophages prior to treatment;
FIGS. 6-4 are glandular diagrams of M2-type macrophages after treatment;
FIG. 7-1 is a graph showing the effect of improving the surface treatment of PEKK implants with sulphonated titanium dioxide;
FIG. 7-2 is a graph showing the effect of improving the surface treatment of PEKK implant surfaces with sulphonation plus nanoactive plus titanium dioxide;
FIGS. 7-3 are graphs showing the effect of improving the surface treatment of PEKK implant surfaces with sulphonation plus nanoactive plus titanium dioxide plus SBF;
FIG. 8 is a graph showing a control of the effect of inhibiting fibroblast proliferation;
FIG. 9 is a graph showing the effect of inhibiting tumor cells;
FIG. 10 is a bar graph showing the number of tumor cells after inhibition;
FIG. 11 is a graph showing a control of the effect of inhibiting melanocytes;
FIG. 12-1 is a flow cytometer of inhibiting melanocytes;
FIG. 12-2 is a flow cytometer B with melanocyte inhibition;
FIG. 12-3 is a flow cytometer C with melanocyte inhibition;
FIGS. 12-4 are flow cytometry charts D of melanocyte inhibition;
fig. 13 is a graph showing the effect of promoting hair growth.
In the figure: 1. the high-voltage power supply system comprises a high-voltage power supply system 11, a transformer primary side I, 12, a transformer primary side II, 13, a transformer secondary side I, 14, a transformer secondary side II, 2, an electrode pair, 2A, an electrode I, 2B, an electrode II, 3, a blocking medium, 4, a working medium, 5, an intelligent sensor, 6, a supply part, 7, a filter layer, 8, an adsorption layer, 9, a nano active substance release port and 10, a component concentration or flow sensor.
Detailed Description
The present invention will be further described in detail with reference to the drawings and examples, in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the detailed description and specific examples, while indicating the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention. In the following description, moreover, descriptions of well-known structures and techniques are omitted so as not to unnecessarily obscure the present invention.
Example 1
Referring to fig. 1, a nano-drug generating device, the main components of which include: a high-voltage power supply system 1, an electrode pair 2, a working medium 4, a filter layer 7, an adsorption layer 8 and a supply member 6.
The electrode pair 2 comprises an electrode I2A and an electrode II 2B, one side of the output end of the high-voltage power supply system 1 is electrically connected with the end part of the electrode I2A, the other side of the output end of the high-voltage power supply system 1 is electrically connected with the end part of the electrode II 2B, and the electrode I2A and the electrode II 2B are oppositely arranged and are not in contact with each other; the electrode I2A and the electrode II 2B are used for loading a high-voltage electric field under the action of the high-voltage power supply system 1.
As a further supplement to the present embodiment, the high-voltage power supply system 1 is a high-voltage power supply or a transformer, and the output high voltage of the high-voltage power supply system 1 is a direct-current or alternating-current high voltage. When the high-voltage power supply system 1 is a transformer, referring to fig. 1, one side of the transformer is a low-voltage input end, the low-voltage input end is a primary side i 11 of the transformer and a primary side ii 12 of the transformer, the other side of the transformer is a high-voltage output end, the high-voltage output end is a secondary side i 13 of the transformer and a secondary side ii 14 of the transformer, and the electrode i 2A and the electrode ii 2B are electrically connected with the secondary side i 13 of the transformer and the secondary side ii 14 of the transformer respectively. The electrode I2A and the electrode II 2B are used for loading a high-voltage electric field under the action of the high-voltage power supply system 11.
As a further supplement of this embodiment, the working medium 4 is discharged in the electron avalanche process under the action of the high-voltage electric field between the electrode i 2A and the electrode ii 2B, so as to obtain at least one nano active substance of ultrafine particles, nitrogen-containing free radicals and oxygen-containing free radicals with particle diameters of 0-1000 nm.
As a further supplement to this embodiment, the adsorption layer 8 is disposed downstream of the electrode pair 2, and is used for adsorbing by-products in the nano-active material.
The adsorption layer 8 is preferably composed of at least one of calcium hydroxide, potassium hydroxide and sodium hydroxide, and is used for adsorbing byproducts such as nitrogen dioxide, ozone and the like so as to improve the purity of the nano-drug.
As a further supplement of this embodiment, the filter layer 7 is disposed downstream of the electrode pair 2, and is used for filtering out particles emitted by the electrode pair 2, particles with a particle size of more than 10 microns, or other impurities entering from the outside, preventing allergy, and improving purity of the nano-drug.
As a further complement to this embodiment, the filter layer 7 is provided at least one of upstream and downstream of the adsorption layer 8.
As a further complement to this embodiment, the blocking medium is a medium with a high dielectric constant, which is placed between the electrode pairs 2 to prevent the electrode pairs 2 from discharging outside the area of the working medium 4, while stabilizing the high voltage electric field and generating uniform ionization.
The electrode pair of the device is different from the electrode pair in the prior art, the electrode pair in the prior art is generally placed in a relatively closed environment, and the electrode pair of the device can be placed in an open environment or a relatively closed environment, so that the same effect can be achieved.
As a further supplement of this embodiment, the nano-drug generating device further includes an intelligent sensor 5, where the intelligent sensor 5 is configured to detect a concentration of at least one nano-active material of ultrafine particles with a particle size of 0-1000 nm, nitrogen-containing free radicals, and oxygen-containing free radicals, and intelligently adjust an operation parameter of the high-voltage power supply system 1, and a composition and a dosage of the working medium 4.
As a further complement to this embodiment, the nano-drug generating device further comprises a supply member 6 for providing the working medium 4 and powering the flow of the working medium 4 for cooling the nano-drug generating device, maintaining an acceptably low temperature level.
As a further complement to this embodiment, the supply part 6 is also provided with a component concentration or flow sensor 10 to maintain a proper composition and dosage of the working medium 4.
As a further supplement to this embodiment, the nano-active material is a low temperature plasma with an electron density of 10 7 -10 23 /cm 3 。
The tail part of the nano medicine generating device is provided with a nano active substance release port 9.
As a further supplement to this embodiment, the working medium 4 is one or more of hyaluronic acid, collagen, steam, hydrogen, methane, oxygen, nitrogen, carbon dioxide, air, rare gas, essential oil, physiological saline or a drug.
As a further complement to this embodiment, the electrode pairs 2 are electrically connected during electron avalanche by means of a partially ionized working medium 4 or a broken down blocking medium.
As a further supplement to this embodiment, the blocking medium and the working medium 4 may be the same medium, for example, may be air, where a part of the working medium 4 is ionized by undergoing an electron avalanche process discharge, and another part is in a dielectric state without being ionized, and is used as the blocking medium.
The blocking medium and the working medium 4 may be different mediums, and in this case, the blocking medium may be disposed on the outer periphery of any electrode of the electrode pair 2, or disposed between the electrode pairs 2. In this embodiment, the electrode pair 2 is disposed through the blocking medium, and the blocking medium also plays a role of fixing the electrode pair 2 at this time, so as to further ensure stability of the electric field.
The electrode pair 2 is any combination of needle shape, bar shape, strip shape, sheet shape, ring shape and the like. In this embodiment, the electrode pairs 2 are each arranged in a needle shape to maintain a local accumulation of the high voltage electric field, which is more likely to induce an electron avalanche process of the working medium 4 to discharge.
As a further supplement to the present embodiment, the output high voltage of the high voltage power supply system 1 is a pulse high voltage. The working temperature is reduced and the biocompatibility of the nano-drug is improved while the nano-drug is manufactured efficiently.
As a further supplement to this embodiment, the nano-active substance not only can be directly used as a nano-drug, but also can be added with other drugs to form a new nano-drug by taking the nano-active substance as a carrier, and can be used for medical purposes, such as skin diseases and wound care, beauty and anti-aging, hair loss prevention and hair growth, oral care, respiratory disease prevention and treatment, tumor treatment and the like.
Example 2.
As a modification of example 1, as shown in fig. 2, one electrode i 2A of the electrode pair 2 is needle-shaped, the other electrode ii 2B is ring-shaped, and the electrode ii 2B is disposed on the circumference of the blocking medium. The blocking medium is also annular and arranged between the electrode pairs 2, so that on one hand, ionization uniformity can be ensured, on the other hand, the electrode II 2B can be prevented from being contacted with the working medium 4, and the electrode II 2B can be prevented from being corroded when the working medium 4 discharges, so that the stability of discharge is ensured. Other features are the same as those of the first embodiment.
The specific experimental data are shown in table 1:
TABLE 1 experiment data table of nano-drug generating device (ambient temperature 25 ℃ C., relative humidity 55%)
As can be seen from table 1 and fig. 3-5: the nano medicine generating device of the embodiment can produce a large amount of nano active substances such as ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals, oxygen-containing free radicals and the like, can generate a large amount of oxygen-containing free radicals (such as hydroxyl and the like), and nitrogen-containing free radicals with the concentration of more than 15-27ppm (such as nitrogen monoxide and the like), and can be used for medical application. In addition, under the same condition, the embodiment adopts pulse high pressure, so that the temperature of the working medium 4 can be reduced and the biocompatibility of the nano-drug can be improved while the nano-drug is manufactured efficiently.
Example 3
The application of a nano-drug generating device for relieving skin diseases comprises that the nano-drug generating device provides a working medium 4 to be subjected to electron avalanche process discharge to generate at least one nano-active substance containing ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals and oxygen-containing free radicals, wherein the nano-active substance or nano-drug taking the nano-active substance as a carrier acts on skin, so that the oxygenation effect and hemoglobin index of the skin are increased, the activation of mast cells and eosinophils is inhibited, the expression and production of IL-6 and TNF-alpha are inhibited, the activation of NF-kappa B is inhibited, and allergic dermatitis is improved.
In this example, allergic eczema is taken as an example. Referring to fig. 6-1, M2 type macrophages are significantly immersed before treatment, the stratum corneum is thicker, and after treatment with nano-active substances, the stratum corneum becomes significantly thinner, referring to fig. 6-2. Referring to fig. 6-3, the glands of M2 type macrophages before treatment are enlarged, and referring to fig. 6-4, the glands of M2 type megaphaga cells become significantly smaller after treatment. Therefore, after the nano active substance acts on the skin, the activation of mast cells and eosinophils is inhibited, and at the same time, the horny layer is thinned and normal, the abnormal keratinization is inhibited, and the allergic eczema is improved.
Example 4
The nanometer medicine generating device is used for generating nanometer active substances for oral care, the nanometer medicine generating device is used for providing a working medium 4 to be discharged in an electron avalanche process to generate at least one nanometer active substance containing ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals and oxygen-containing free radicals, the nanometer active substances or nanometer medicine taking the nanometer active substances as a carrier acts on gingiva, periodontal or an implant, the hydrophilicity of the surface of the nanometer active substances is improved, bacteria inhibition and inflammation diminishing are realized, periodontitis is relieved, the growth of osteoblasts or tissue cells is promoted, wound healing is improved, and the success rate of the implant is improved.
In this embodiment, the nano-active material acts on the implant, and as exemplified by PEKK implant, the higher the density of these small particles, the more favorable the healing of the implant, as shown in fig. 7-1, fig. 7-2 and fig. 7-3, the PEKK implant.
Referring to fig. 7-1, fig. 7-2 and fig. 7-3, sulfonation plus titanium dioxide surface treatment followed by deposition of hydroxyapatite in sbf demonstrated in vitro osteogenic capacity. Experiments show that the effect of replacing the sulfonation step with nano-drugs is equivalent to sulfonation plus titanium dioxide surface treatment. If the titanium dioxide is sulfonated firstly and then treated by nano-drugs, the deposition of titanium dioxide can be promoted, the deposition of hydroxyapatite in sbf can be better induced, the growth of osteoblasts or tissue cells can be promoted, bacteria inhibition and inflammation diminishing can be realized, and the success rate of the implant can be improved.
Example 5
The application of the nano-drug generating device for relieving respiratory diseases comprises that the nano-drug generating device provides a working medium 4 to be subjected to electron avalanche process discharge to generate at least one nano-active substance containing ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals and oxygen-containing free radicals, and the nano-active substance or the nano-drug taking the nano-active substance as a carrier acts on respiratory tract, so that tissue oxygenation is improved, vasodilation is promoted, the level of inflammatory medium is improved, and regeneration of damaged tissue cells is promoted.
In this example, the nano-active substance acts on the respiratory tract, and lung fibrosis caused by interstitial pneumonia is exemplified as shown in fig. 8, wherein small dots represent fibroblasts, and the higher the density of small dots, the more fibroblasts are shown.
The nano medicine can improve tissue oxygenation, promote vasodilation, improve the level of inflammatory mediators, obviously inhibit the proliferation of fibrocyte (the inhibition rate is up to more than 80 percent) and promote the regeneration of injured tissue cells.
Example 6
The application of the nano-drug generating device for generating nano-active substances to inhibit tumor cells is that the nano-drug generating device provides a working medium 4 to be subjected to electron avalanche process discharge to generate at least one nano-active substance containing ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals and oxygen-containing free radicals, the nano-active substance or nano-drug taking the nano-active substance as a carrier acts on the tumor cells to activate giant phagocytes, T cells or NK cells, induce the immunogenic cell death of the tumor cells, trigger specific and protective immune response of the system, polarize cell membranes, induce oxidative stress reaction and induce the iron death of the tumor cells.
In this example, the nano-active substance acts on lung cancer cells, as shown in fig. 9, after the nano-drug acts for 1 minute, 8 minutes and 16 minutes, the inhibition rate of the lung cancer cells is 50%, 70% and 100% respectively, the lung cancer cells are completely inhibited, macrophages, T cells or NK cells are activated, immunogenic cell death of tumor cells is induced, and the system triggers specific and protective immune response while iron death of tumor cells is induced.
Referring to FIG. 10, a bar graph of viable cell count after tumor cell inhibition is shown. Referring specifically also to Table 2, the number of living cells 282X (10≡6) in the untreated control group, and the number of tumor cells that survived 1 minute, 8 minutes and 16 minutes after the nanoactive material was 141X (10≡6), 86X (10≡6) and 0.5X (10≡6), respectively, were almost completely inhibited.
TABLE 2
Example 7
The nanometer medicine generating device is used for generating nanometer active substances for whitening and resisting aging, the nanometer medicine generating device is used for providing a working medium 4 to be subjected to electron avalanche process discharge to generate at least one nanometer active substance containing ultrafine particles with the particle size of 0-1000 nanometers, nitrogen-containing free radicals and oxygen-containing free radicals, the nanometer active substance or nanometer medicine taking the nanometer active substance as a carrier acts on skin, the oxygen interaction and tissue perfusion of the skin are increased, surface photoaged epidermal cells are removed, the growth of collagen of the skin below is promoted, vascular endothelial growth factors are activated, and the expression and tissue regeneration of anti-aging genes are promoted.
Referring to fig. 11, fig. 12-1, fig. 12-2, fig. 12-3 and fig. 12-4, taking B16 melanocytes as an example, the proliferation of melanocytes is remarkably inhibited (the inhibition rate is more than 50%), the apoptosis of melanocytes is promoted, and after Hyaluronic Acid (HA) combined treatment is added, the apoptosis of melanocytes is further accelerated, which is beneficial to whitening and promotes the expression of anti-aging genes and tissue regeneration.
In this embodiment, the working medium 4 is preferably one or more of hyaluronic acid, collagen, and air.
Example 8
The nano-active substance or the nano-drug taking the nano-active substance as a carrier acts on scalp to promote the production of adenosine triphosphate, activate the DNA transcription factor of NF-kappa B, HIF-1, promote cell proliferation, improve the levels of cytokines, growth factors and inflammatory mediators, improve tissue oxygenation and promote hair growth.
Referring to fig. 13 and table 3, taking the mouse experiment as an example, finasteride treatment with nanoactive for 8 weeks, 5% concentration for 8 weeks, and finasteride treatment with 1 mg/day for 4 weeks, respectively, a statistically significant increase in peripheral hair density was observed, hair growth was promoted, and the concentration and fullness of hair were improved as a whole, and the hair increment of the nanodrug treatment group (8 weeks) was comparable to the test effect of finasteride treatment with 5% concentration for 8 weeks, and finasteride treatment with 1 mg/day for 4 weeks.
TABLE 3 Table 3
The above is only a specific embodiment of the present invention, but the technical features of the present invention are not limited thereto. Any simple changes, equivalent substitutions or modifications made on the basis of the present invention to solve the substantially same technical problems and achieve the substantially same technical effects are encompassed within the scope of the present invention.
Claims (1)
1. The utility model provides a nano-drug generating device, includes high voltage power supply system and electrode pair, electrode pair includes electrode I and electrode II, one side electricity of high voltage power supply system's output is connected electrode I's tip, the opposite side electricity of high voltage power supply system's output is connected electrode II's tip, its characterized in that: the electrode I and the electrode II are oppositely arranged and are not contacted with each other;
the electrode I and the electrode II are used for loading a high-voltage electric field under the action of a high-voltage power supply system;
the nano medicine generating device also at least comprises a working medium, wherein the working medium is subjected to electron avalanche process discharge under the action of a high-voltage electric field between the electrode I and the electrode II, so that at least one nano active substance of ultrafine particles, nitrogen-containing free radicals and oxygen-containing free radicals with the particle size of 0-1000 nanometers is obtained;
the nano medicine generating device also comprises a blocking medium, wherein the blocking medium is a medium with high dielectric constant, and the blocking medium is arranged between the electrode pairs and is used for preventing the electrode pairs from discharging outside the working medium area, stabilizing a high-voltage electric field and generating uniform ionization;
the electrode pairs are needle-shaped and penetrate through the blocking medium; or the electrode I is needle-shaped, the electrode II and the blocking medium are ring-shaped, the electrode II is arranged on the circumference of the blocking medium, and the blocking medium is arranged between the electrode I and the electrode II;
the nano medicine generating device also comprises an adsorption layer, wherein the adsorption layer is arranged at the downstream of the electrode pair and is used for adsorbing byproducts in nano active substances; the adsorption layer comprises at least one of calcium hydroxide, potassium hydroxide and sodium hydroxide and is used for adsorbing nitrogen dioxide and ozone;
the nano medicine generating device also comprises a filter layer, wherein the filter layer is arranged at the downstream of the electrode pair and is used for filtering out particles emitted by the electrode pair, particles with the particle size of more than 10 microns or other impurities entering from the outside; the filter layer is arranged at least one of the upstream and downstream of the adsorption layer;
the nano-drug generating device further comprises a supply component for providing a working medium and providing power for the flow of the working medium to cool the nano-drug generating device and maintain an acceptably low temperature level; the supply part is also provided with a component concentration or flow sensor so as to maintain proper components and dosage of the working medium;
the nano medicine generating device further comprises an intelligent sensor, wherein the intelligent sensor is used for detecting the concentration of at least one nano active substance of ultrafine particles, nitrogen-containing free radicals and oxygen-containing free radicals with the particle size of 0-1000 nanometers, and intelligently adjusting the working parameters of the high-voltage power supply system, the components and the dosage of the working medium;
the tail part of the nano medicine generating device is provided with a nano active substance release port.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110678804.7A CN113456663B (en) | 2021-06-18 | 2021-06-18 | Nanometer medicine generating device and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110678804.7A CN113456663B (en) | 2021-06-18 | 2021-06-18 | Nanometer medicine generating device and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113456663A CN113456663A (en) | 2021-10-01 |
| CN113456663B true CN113456663B (en) | 2023-10-24 |
Family
ID=77868628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110678804.7A Active CN113456663B (en) | 2021-06-18 | 2021-06-18 | Nanometer medicine generating device and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113456663B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116092631A (en) * | 2023-01-17 | 2023-05-09 | 湖南安泰康成生物科技有限公司 | Tumor treatment system combining iron death inducer and electric field |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108479658A (en) * | 2018-05-28 | 2018-09-04 | 杭州清稞节能环保科技有限公司 | A kind of graphene nano steam generation facility and beauty instrument |
| CN209253563U (en) * | 2018-05-28 | 2019-08-16 | 杭州清稞节能环保科技有限公司 | Efficient nano steam generation facility and beauty instrument |
| CN110192975A (en) * | 2019-05-31 | 2019-09-03 | 杭州清稞节能环保科技有限公司 | A kind of nanoparticle beauty steam generation facility |
| CN112312638A (en) * | 2020-11-10 | 2021-02-02 | 杭州清稞科技有限公司 | High-activity low-temperature plasma, preparation method and application thereof |
-
2021
- 2021-06-18 CN CN202110678804.7A patent/CN113456663B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108479658A (en) * | 2018-05-28 | 2018-09-04 | 杭州清稞节能环保科技有限公司 | A kind of graphene nano steam generation facility and beauty instrument |
| CN209253563U (en) * | 2018-05-28 | 2019-08-16 | 杭州清稞节能环保科技有限公司 | Efficient nano steam generation facility and beauty instrument |
| CN110192975A (en) * | 2019-05-31 | 2019-09-03 | 杭州清稞节能环保科技有限公司 | A kind of nanoparticle beauty steam generation facility |
| CN112312638A (en) * | 2020-11-10 | 2021-02-02 | 杭州清稞科技有限公司 | High-activity low-temperature plasma, preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 多针-板直流放电纳米水离子发生器电极结构研究;张馨方等;《建筑热能通风空调》;20210228;第40卷(第2期);第43-47页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113456663A (en) | 2021-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10500407B2 (en) | Apparatus for atmospheric pressure pin-to-hole spark discharge and uses thereof | |
| US6350785B2 (en) | Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors | |
| KR101100631B1 (en) | A topical composition comprising particulates comprising a first conductive material and a second conductive material | |
| JP2020072974A (en) | Cell activation method and cell activation device | |
| Kuo | Air plasma for medical applications | |
| CN113456663B (en) | Nanometer medicine generating device and application | |
| KR102403490B1 (en) | Method for treating or preventing keloids with non thermal plasma treated solution | |
| JP6890198B2 (en) | Method for producing cell activator for wound treatment or anti-inflammatory | |
| TWI702051B (en) | Efficient nano spot lightening, brightening, moisturizing activator and its preparation method | |
| CN111068185A (en) | Plasma hair-growing comb | |
| CN114053300A (en) | Application of cerium oxide nanoenzyme with active oxygen scavenging capacity in treating alopecia | |
| CN211634932U (en) | Plasma hair-growing comb | |
| KR20170130742A (en) | Cosmetic Composition For Regenerating skin | |
| CN113473689A (en) | Low-temperature plasma generating device and application | |
| CN108463046B (en) | Hand-held air electric spark cold plasma shock wave jet device | |
| Wang et al. | Extracellular vesicles in skin health, diseases, and aging | |
| Peña-Eguiluz et al. | Acute neck radiodermatitis treated by nonthermal plasma therapy: case report | |
| CN113365406A (en) | Low-temperature plasma generating device and application | |
| KR102120552B1 (en) | Composition for skin-soothing comprising liquid type plasma | |
| Huang et al. | Application of non-pharmacologic therapy in hair loss treatment and hair regrowth | |
| Li et al. | Insights into the role of mesenchymal stem cells in cutaneous medical aesthetics: from basics to clinics | |
| RU2414257C2 (en) | Method of treating acne by horny layering | |
| CN114392485A (en) | Oral cavity low-temperature plasma disinfection method and low-temperature plasma generating device | |
| Pastrana-López | Journal of Stem Cell Research | |
| Chen et al. | Plasma Medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |